Erik Fink Eriksen

Summary

Affiliation: University of Oslo
Country: Norway

Publications

  1. ncbi Cellular mechanisms of bone remodeling
    Erik Fink Eriksen
    Department of Clinical Endocrinology, Oslo University Hospital, Aker, Trondheimsveien 235, 0514 Oslo, Norway
    Rev Endocr Metab Disord 11:219-27. 2010
  2. ncbi Treatment of osteopenia
    Erik Fink Eriksen
    Department of Clinical Endocrinology, Oslo University Hospital, Aker, Trondheimsveien 235, 0514, Oslo, Norway
    Rev Endocr Metab Disord 13:209-23. 2012
  3. ncbi Hormone replacement therapy or SERMS in the long term treatment of osteoporosis
    E F Eriksen
    Department of Endocrinology, Oslo University Hospital, Oslo, Norway
    Minerva Ginecol 64:207-21. 2012
  4. ncbi The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats
    Astrid K Stunes
    Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, NTNU, Trondheim, Norway
    BMC Endocr Disord 11:11. 2011
  5. ncbi Bone turnover and metabolism in patients with early multiple sclerosis and prevalent bone mass deficit: a population-based case-control study
    Stine Marit Moen
    Department of Neurology, Oslo University Hospital Ulleval, Oslo, Norway
    PLoS ONE 7:e45703. 2012

Collaborators

  • Trygve Holmøy
  • Magritt Brustad
  • Stine Marit Moen
  • Astrid K Stunes
  • Leiv Sandvik
  • Elisabeth Gulowsen Celius
  • Lars Nordsletten
  • Unni Syversen
  • Bjorn I Gustafsson
  • Reidar Fossmark
  • Jan H Waarsing
  • Irene Westbroek
  • Christiane Petzold
  • Janne E Reseland

Detail Information

Publications5

  1. ncbi Cellular mechanisms of bone remodeling
    Erik Fink Eriksen
    Department of Clinical Endocrinology, Oslo University Hospital, Aker, Trondheimsveien 235, 0514 Oslo, Norway
    Rev Endocr Metab Disord 11:219-27. 2010
    ..The dominant pathway regulating osteoclast recruitment is the RANKL/OPG system, while many different factors (RUNX, Osterix) are involved in osteoblast differentiation. Both pathways are modulated by calcitropic hormones...
  2. ncbi Treatment of osteopenia
    Erik Fink Eriksen
    Department of Clinical Endocrinology, Oslo University Hospital, Aker, Trondheimsveien 235, 0514, Oslo, Norway
    Rev Endocr Metab Disord 13:209-23. 2012
    ....
  3. ncbi Hormone replacement therapy or SERMS in the long term treatment of osteoporosis
    E F Eriksen
    Department of Endocrinology, Oslo University Hospital, Oslo, Norway
    Minerva Ginecol 64:207-21. 2012
    ....
  4. ncbi The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats
    Astrid K Stunes
    Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, NTNU, Trondheim, Norway
    BMC Endocr Disord 11:11. 2011
    ..abstract:..
  5. ncbi Bone turnover and metabolism in patients with early multiple sclerosis and prevalent bone mass deficit: a population-based case-control study
    Stine Marit Moen
    Department of Neurology, Oslo University Hospital Ulleval, Oslo, Norway
    PLoS ONE 7:e45703. 2012
    ..The aim of this study was to explore the mechanism of the low bone mass in early-stage MS patients...